BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
BIOMERICA INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026
$1.76−0.09 (-4.86%)
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
BIOMERICA INC revenue by segment
By business segment
By product or service
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Lab [Member] | $411.00K | $621.00K | $676.00K | $1.02M | $498.00K | $627.00K | $777.00K | $1.28M | $553.00K | $404.00K | $992.00K | $1.29M | 47.0% | -17.5% |
| Contract Manufacturing [Member] | $359.00K | $167.00K | $172.00K | $192.00K | $150.00K | $320.00K | $260.00K | $339.00K | $211.00K | $281.00K | $131.00K | $117.00K | 41.0% | +139.3% |
| Over-The-Counter [Member] | $102.00K | $197.00K | – | – | $97.00K | $170.00K | – | $187.00K | $348.00K | $329.00K | $443.00K | $303.00K | 11.7% | +5.2% |
| Physician's office [Member] | $3.00K | $2.00K | $1.00K | $3.00K | $4.00K | $2.00K | $3.00K | $3.00K | $4.00K | $3.00K | $1.00K | $4.00K | 0.3% | -25.0% |
| Over -the-Counter [Member] | – | – | $361.00K | $161.00K | – | $170.00K | $596.00K | $187.00K | – | $329.00K | $443.00K | – | – | – |
By region
| Revenue | Q4 26 | Q3 26 | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America [Member] | $446.00K | $259.00K | $443.00K | $318.00K | $277.00K | $404.00K | $551.00K | $427.00K | $216.00K | $393.00K | $320.00K | $355.00K | 51.0% | +61.0% |
| Europe [Member] | $263.00K | $287.00K | $262.00K | $305.00K | $318.00K | $198.00K | $311.00K | $470.00K | $353.00K | $331.00K | $428.00K | $327.00K | 30.1% | -17.3% |
| Asia [Member] | $110.00K | $270.00K | $358.00K | $670.00K | $104.00K | $365.00K | $431.00K | $817.00K | $38.00K | $210.00K | $606.00K | $1.03M | 12.6% | +5.8% |
| Middle East [Member] | $53.00K | $171.00K | $137.00K | $85.00K | $50.00K | $149.00K | $341.00K | $90.00K | $509.00K | $78.00K | $212.00K | – | 6.1% | +6.0% |
| South America [Member] | $3.00K | $0 | $10.00K | $2.00K | $0 | $3.00K | $2.00K | $3.00K | $0 | $5.00K | $1.00K | $5.00K | 0.3% | – |
From the segment and revenue-disaggregation notes of Biomerica's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.